None listed
Conditions
Brief summary
This study aims to develop a multi-centre trial and to assess which children with acute respiratory failure benefit using Nasal High Flow Therapy (NHF). For this purpose we will perform a randomised controlled trial comparing current best practice (standard oxygen delivery via subnasal prongs, facemask, venturi mask) versus NHF therapy. With the introduction of this simple to use respiratory system in regional and tertiary centres we aim to investigate if NHF therapy has a lower treatment failure rate in comparison to standard oxygen delivery reducing the hospital length of stay.
Interventions
Nasal High Flow Oxygen Delivery at a weight prescribed flow rate for the duration of oxygen requirement. Initially FiO2 is set at 0.21 and SpO2 observed for 10 minutes. If SpO2 remains less than 90/92% (hospital threshold dependent) after 10 minutes then FiO2 is increased and titrated to achieve SpO2 greater than or equal to 90/92%. If patient presents with SpO2 less than 85% then FiO2 is immediately increased to achieve SpO2 equal to or greater than 90/92%. FiO2 is adjusted to achieve and maint
Nasal High Flow Oxygen Delivery at a weight prescribed flow rate for the duration of oxygen requirement. Initially FiO2 is set at 0.21 and SpO2 observed for 10 minutes. If SpO2 remains less than 90/92% (hospital threshold dependent) after 10 minutes then FiO2 is increased and titrated to achieve SpO2 greater than or equal to 90/92%. If patient presents with SpO2 less than 85% then FiO2 is immediately increased to achieve SpO2 equal to or greater than 90/92%. FiO2 is adjusted to achieve and maintain SpO2 of 90/92-98% avoiding long periods of hyperoxia with SpO2 of 100%. For any flow rates greater than 25 L/min the flow rates are increased gradually over two minutes at commencement, and observe how the flow rates are tolerated. These alterations are made by the treating physician or nurse in attendance and recorded on the patients respiratory observation chart.
Sponsors
Paediatric Critical Care Research Group
Study design
Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Open (masking not used)
Eligibility
Sex/Gender
All
Age
1 Years to 4 Years
Healthy volunteers
No
Inclusion criteria
Children aged 1-4 years of age (up to but excluding 5th birthday) with the clinical diagnosis of an Acute Hypoxemic Respiratory Failure disease process such as acute lower respiratory tract infection or asthma, or pnuemonia as examples, and an oxygen requirement in room air (SpO2 <90/92%) Included are infants with reactive airway disease >12 months and an oxygen requirement in room air (SpO2 <90/92%). This includes infants >12 months with the diagnosis of bronchiolitis Informed consent from parents or guardians
Exclusion criteria
Oxygen requirement and therapy in the emergency department existed for longer than 4 hours prior to inclusion (excludes oxygen given in ambulance or other hospital) Previous use of NHF therapy Upper airway obstruction Craniofacial malformations Critically ill infants requiring immediate higher level of respiratory support i.e. NIV or invasive ventilation, low level of consciousness. Basal skull fracture Cyanotic Heart Disease Home Oxygen therapy Apnoeas (defined as requiring respiratory support such as NIV or mechanical ventilation) Trauma Cystic Fibrosis Oncology patients Palliative Care patients Child protection case
Outcome results
None listed